Lantern Pharma Announces Establishment Of A.I. Center Of Excellence And Advanced Agentic Labs In Bengaluru, India

• The A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engineering, development and refinement of state-of-the-art ML-ready disease models and integration with global biopharma customers and partners.
• This strategic initiative positions Lantern to scale its proven AI capabilities and platform across oncology and into new disease categories, meeting growing biopharma partner demand.
• Hiring for initial positions has already been initiated and Lantern anticipates that expansion and hiring will be cash flow neutral to the Company.

Lantern Pharma Inc. (NASDAQ:LTRN), a pioneer in AI-driven precision oncology and computational therapeutic development, today announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India. This strategic initiative represents a critical inflection point in Lantern's evolution—transitioning from pioneering AI-enabled drug discovery in cancer to industrializing those capabilities at global scale for the broader drug development community.